Effect Of Intraperitoneal Chemotherapy On Survival For Ovarian Cancer In Clinical Practice And Frequency Of Use.

5576 Background: In 2006 the National Cancer Institute (NCI) issued a rare clinical alert recommending intraperitoneal chemotherapy (IP) to treat ovarian cancer after GOG-172, a randomized clinical trial comparing IP and intravenous chemotherapy (IV), demonstrated a 16-month survival advantage with IP. The aims of this study were to determine: (1) changes in IP utilization over time, (2) factors associated with adoption of IP therapy, and (3) the impact of IP on survival. Methods: Prospective cohort study of women with stage III, optimally-cytoreduced ovarian cancer treated at National Comprehensive Cancer Network (NCCN) institutions. Trends were evaluated in 823 patients between 2003-2012. In 603 patients, diagnosed after 2006, multivariable logistic regression and propensity-score analyses were used to examine factors associated with receipt of IP therapy and associations between treatment modality, adverse events, and overall survival. Results: IP utilization rose from 0% to 33% between 2003-2006, incr...